TY - JOUR
T1 - The 4830C > A polymorphism within intron 5 affects the pattern of alternative splicing occurring within exon 6 of the thrombopoietin gene
AU - Webb, Karen E.
AU - Martin, John F.
AU - Cotton, James
AU - Erusalimsky, Jorge D.
AU - Humphries, Steve E.
PY - 2003/6/1
Y1 - 2003/6/1
N2 - Objective. A common variant in intron 5 of the thrombopoietin (TPO) gene (4830C > A) has been associated with risk of myocardial infarction (MI). To explore the molecular mechanism of this association, the ability of the intron to act as a transcription enhancer and to influence mRNA splicing was tested. Method and Results. In HepG2 cells the presence of intron 5 upstream of the TPO promoter decreased promoter activity to between 60% and 30%. This effect was orientation dependent; in the reverse orientation, intron 5 caused a twofold greater decrease in promoter activity compared to the forward orientation. However, the effects were similar with either the C or the 4830A allele. An in vitro exon trapping system was used to study the effect of the polymorphism on splicing events in exon 6. The full-length (TPO-1) and three previously reported splice variants (TPO-2, TPO-3, and TPO-5) were identified. The 4830A allele resulted in a small but statistically significant increase in production of the TPO-3 splice variant relative to the full-length transcript (10.6%±0.6%) compared to the 4830C allele (8.3%±0.6%) (p = 0.02). Generation of TPO-5 was also slightly increased, but this did not reach significance. Conclusion. The identification of a potential "silencer" sequence in intron 5 of the TPO gene demonstrates the complexity of control of expression of the gene. Although the precise role of the different splice variants is not known, the finding that the 4830C > A sequence changealters their relative amounts, suggests a possible molecular mechanism whereby TPO genotype may influence the risk of MI.
AB - Objective. A common variant in intron 5 of the thrombopoietin (TPO) gene (4830C > A) has been associated with risk of myocardial infarction (MI). To explore the molecular mechanism of this association, the ability of the intron to act as a transcription enhancer and to influence mRNA splicing was tested. Method and Results. In HepG2 cells the presence of intron 5 upstream of the TPO promoter decreased promoter activity to between 60% and 30%. This effect was orientation dependent; in the reverse orientation, intron 5 caused a twofold greater decrease in promoter activity compared to the forward orientation. However, the effects were similar with either the C or the 4830A allele. An in vitro exon trapping system was used to study the effect of the polymorphism on splicing events in exon 6. The full-length (TPO-1) and three previously reported splice variants (TPO-2, TPO-3, and TPO-5) were identified. The 4830A allele resulted in a small but statistically significant increase in production of the TPO-3 splice variant relative to the full-length transcript (10.6%±0.6%) compared to the 4830C allele (8.3%±0.6%) (p = 0.02). Generation of TPO-5 was also slightly increased, but this did not reach significance. Conclusion. The identification of a potential "silencer" sequence in intron 5 of the TPO gene demonstrates the complexity of control of expression of the gene. Although the precise role of the different splice variants is not known, the finding that the 4830C > A sequence changealters their relative amounts, suggests a possible molecular mechanism whereby TPO genotype may influence the risk of MI.
UR - http://www.scopus.com/inward/record.url?scp=0038387796&partnerID=8YFLogxK
U2 - 10.1016/S0301-472X(03)00065-1
DO - 10.1016/S0301-472X(03)00065-1
M3 - Article
C2 - 12829024
AN - SCOPUS:0038387796
SN - 0301-472X
VL - 31
SP - 488
EP - 494
JO - Experimental Hematology
JF - Experimental Hematology
IS - 6
ER -